Cogent Biosciences, Inc. (COGT)
| Market Cap | 316.15M |
| Revenue (ttm) | 7.87M |
| Net Income (ttm) | -179.21M |
| Shares Out | 37.19M |
| EPS (ttm) | -16.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $8.50 |
| Previous Close | $9.08 |
| Change ($) | -0.58 |
| Change (%) | -6.39% |
| Day's Open | 9.10 |
| Day's Range | 8.32 - 9.25 |
| Day's Volume | 434,524 |
| 52-Week Range | 0.36 - 14.44 |
BOULDER, Colo. and CAMBRIDGE, Mass.
Cogent Biosciences, Inc. (COGT) delivered earnings and revenue surprises of -1910.00% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th...
CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announ...
CAMBRIDGE, Mass., Feb. 22, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...
CAMBRIDGE, Mass., Feb. 18, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...
CAMBRIDGE, Mass., Feb. 11, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...
CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, tod...
CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announce...
CAMBRIDGE, Mass., Nov. 30, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...
CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...
CAMBRIDGE, Mass., Nov. 12, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announc...
CAMBRIDGE, Mass., Oct. 26, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. ("Cogent") (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, to...
CAMBRIDGE, Mass., Oct. 5, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biotechnology company focused on developing precision therapies for genetically defined diseases, today a...
Is (UMRX) Outperforming Other Medical Stocks This Year?
CAMBRIDGE, Mass., Aug. 31, 2020 /PRNewswire/ -- Unum Therapeutics Inc.
CAMBRIDGE, Mass., Aug. 11, 2020 /PRNewswire/ -- Unum Therapeutics Inc.
On Aug 6, the Nasdaq Composite Index topped the milestone of 11,000. The tech-heavy laden completed its 1000-point journey in 40 trading days, representing the fastest ever rise in 20 years.
Is (UMRX) Outperforming Other Medical Stocks This Year?
Unum Therapeutics Inc. (UMRX) closed the most recent trading day at $2.74, moving +1.86% from the previous trading session.
PHILADELPHIA, July 21, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Unum Therapeutics Inc. (NASDAQ: UMRX) ("Unum" or the "Company") on behalf of the Company's investors.
Top Ranked Momentum Stocks to Buy for July 17th
Top Ranked Momentum Stocks to Buy for July 10th
As of late, it has definitely been a great time to be an investor in Unum Therapeutics Inc. (UMRX).
Unum Therapeutics (UMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Unum Therapeutics (UMRX) stock is on the rise Tuesday following the acquisition of private biotechnology company Kiq on Monday. The post Unum Therapeutics: Why UMRX Stock Is Shooting 7% Higher Today app...
CAMBRIDGE, Mass. and PHILADELPHIA, July 6, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biopharmaceutical company focused on developing therapies for solid tumors, today announ...
Unum Therapeutics Inc (UMRX) delivered earnings and revenue surprises of 39.39% and 134.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
During Unum Therapeutics' (UMRX) upcoming Q1 earnings call, investor focus will be on the company's progress pertaining to its preclinical program, BOXR1030, for treating solid tumor cancers.
Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of 120.00% and 271.07%, respectively, for the quarter ended December 2019.
CAMBRIDGE, Mass., March 20, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced ...
Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
BOXR1030 is a GPC3-targeted CAR T cell incorporating the novel GOT2 transgene designed to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism
-Cohort 1 enrollment is complete with no dose-limiting toxicities observed-
-Clinical response and safety data with ACTR707 provide proof-of-mechanism for the ACTR platform and support the ongoing Phase 1 dose-escalation trial in relapsed or refractory NHL- -Clinical response a...
Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of -25.81% and -76.87%, respectively, for the quarter ended September 2019.
Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today an...
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Unum (UNM) have what it takes?
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today a...
Unum (UNM) reported earnings 30 days ago. What's next for the stock?
CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today an...
Unum Therapeutics Inc. (UMRX) CEO Chuck Wilson on Q2 2019 - Earnings Call Transcript
Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of 12.82% and 1.36%, respectively, for the quarter ended June 2019.
Unum Group (UNM) CEO Richard McKenney on Q2 2019 Results - Earnings Call Transcript
Unum (UNM) delivered earnings and revenue surprises of 1.49% and 1.22%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Unum (UNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As of late, it has definitely been a great time to be an investor in Unum Therapeutics.
Unum Therapeutics Inc (NASDAQ: UMRX) shares were under pressure Wednesday following a clinical trial update provided by the company late Tuesday.
Shares of Unum Therapeutics Inc. tumbled 19% toward a record low in premarket trading Wednesday, after the Food and Drug Administration placed a "clinical hold" on the phase 1 trial of its cancer treatm...
Unum Therapeutics Inc.'s (UMRX) CEO Chuck Wilson on Q1 2019 Results - Earnings Call Transcript
About COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and ... [Read more...]
| Industry Biotechnology | IPO Date Mar 29, 2018 |
| Stock Exchange NASDAQ | Ticker Symbol COGT |
Financial Performance
In 2020, COGT's revenue was $7.87 million, a decrease of -65.02% compared to the previous year's $22.50 million. Losses were -$179.21 million, 463.0% more than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price forecast is 20.67, which is an increase of 143.18% from the latest price.